What happened to longevity while you weren't looking
Last week, a patient walked into a longevity clinic and asked about an AI-discovered senolytic she'd heard on a podcast. It was already in Phase II trials. Her doctor, a Mount Sinai-trained physician, hadn't heard of it. That scene, described in MedCity News, captures where the longevity sector stands right now: the science is moving faster than the people trained to use it.
Something shifted in Q1 2026. Not a single breakthrough, but a convergence. Capital, science, consumer behaviour, and the global events circuit all tilted in the same direction at the same time. The result doesn't look like a trend any more. It looks like an industry finding its shape.
The capital speaks first
Between January and March 2026, longevity biotech raised approximately $3.74 billion across 49 financing events, a 56% uplift over the same quarter last year. The median deal sat at $21.8 million, which tells you something important: these aren't seed-stage bets any more. Companies are graduating into later rounds, and serious institutional money is following them.
The headline deal: Eli Lilly committed $2.75 billion to Insilico Medicine for AI-discovered drug candidates. Insilico has 28 drugs in its pipeline, nearly half already in clinical trials. Their first compound went from target identification to Phase I in under 30 months. Traditional pharma averages four to six years for the same milestone. Lilly is also reportedly planning a longevity-focused trial evaluating tirzepatide's effects on biological ageing. When the company behind Mounjaro and Zepbound places parallel bets on AI discovery and geroscience, you're watching the formation of what could become the first longevity Big Pharma.
Full-year projections for 2026 now converge around $8 to $9 billion in total longevity biotech investment, roughly 55 to 60% growth over 2025. Even stripped of outliers, the signal is clear: the money isn't speculating any more. It's deploying.
AI rewrites the drug discovery clock
The Lilly deal isn't isolated. As of early 2026, more than 📊 173 AI-discovered programmes are in clinical development: 94 in Phase I, 56 in Phase II, and 15 approaching Phase III. Early performance data is striking: AI-discovered compounds show 80 to 90% Phase I success rates compared to a historical average of 40 to 65%.
The caution: Phase III is where most drugs fail, and the AI pipeline is only now reaching that stage. We'll know a lot more by year-end. But the direction of travel is unmistakable. Gero has signed a research agreement with Chugai Pharmaceutical for AI-discovered therapies targeting age-related diseases. Biophytis presented its AI longevity platform at NVIDIA GTC 2026. Scripps Research used AI to identify novel anti-ageing candidates that extended lifespan in animal models, with over 70% of compounds showing significant results.
What's happening here is bigger than a pipeline update. For decades, pharma R&D has been governed by Eroom's law: the observation that drug discovery gets slower and more expensive over time, the inverse of Moore's law. AI may be the force that finally breaks the pattern. As biotech researcher Jacob Kimmel puts it: "We are entering an epoch of abundant intelligence. The therapies that emerge could serve as the counterexample that downgrades Eroom's law to a historic conjecture." His conclusion is hard to argue with: "There is no product more valuable than healthy time."
The practical consequence for clinicians is uncomfortable but real. More therapeutic options, multiplied by more data per option, multiplied by the same number of clinical hours, equals something that breaks. Longevity clinics are already struggling with the learning curve: building their own frameworks without universal clinical pathways, trying to separate what is merely measurable from what is truly meaningful for the patient. The doctors who will thrive when these therapeutics arrive are the ones building the data infrastructure now, not memorising every new compound.
The body is not a parts list
While AI accelerates discovery, the scientific conversation about what ageing actually is, is shifting too.
This week, the International Conference on Targeting Longevity in Berlin will challenge the prevailing approach of treating ageing as a sequence of isolated molecular defects. The proposition: ageing isn't a checklist of broken parts. It's a loss of coordination between systems: mitochondria, microbiota, immune signalling, and metabolism all talking past each other.
There's clinical weight behind this reframing. The FDA last year granted accelerated approval to elamipretide (marketed as Forzinity), the first approved mitochondria-targeted therapeutic. Stealth BioTherapeutics, the company behind it, is now advancing pipeline candidates for dry age-related macular degeneration and neurodegenerative disorders. Their CSO, David Brown, frames it simply: "Life is bioenergetics. The basis of life is grounded in eating food and breathing air and having our mitochondria take those two things together and provide energy."
Meanwhile, a team using elamipretide has advanced to the semi-finals of the $101 million XPRIZE Healthspan competition, testing whether treating mitochondrial dysfunction can counter functional decline in healthy older adults. The pilot study has completed data collection, with results expected at the American Aging Association meeting in June.
This isn't fringe. 🌍 The longevity events circuit tracked 349 events across 42 countries in Q1, a 71% year-over-year increase. The speaker mix tells its own story: C-suite executives now match academics at 25% each, a structural shift from what was historically a research-dominated circuit. Stanford, the National University of Singapore, and Harvard Medical School remain the top contributing institutions, but Retro Biosciences, Technogym, and Fountain Life are among the most committed sponsors. The audience has changed. The questions have changed.
What the next twelve months look like
The honest forecast: we're in the early innings of a decade-long transformation, and this year will deliver both genuine breakthroughs and necessary corrections.
On the science side, watch Phase III results from AI-discovered compounds arriving in late 2026. If early success rates hold, the therapeutic toolkit available to longevity clinicians will expand dramatically. If they don't, expect a recalibration, not a retreat.
🚨 There's also an urgency that doesn't get enough attention. A study tracking cause-of-death data from 1979 to 2023 found that people born between 1970 and 1985 are experiencing higher mortality rates than previous generations, driven by cardiovascular disease, cancer, and lifestyle factors. As epidemiologist Leah Abrams (Tufts University) asked: "If these cohorts are showing worse mortality trends already, what's going to happen when they reach their 60s if nothing changes?" Longevity isn't a luxury interest. For an entire generation, it's a course correction.
On the consumer side, the market is already here. 115 startups were mapped last week by New Economies across longevity clinics, wearables, diagnostics, and supplements. Biohackers World just drew record attendance of 2,000 people in Los Angeles.
The cultural signals are just as loud. Jane Fonda and Dr. Mark Hyman are headlining a women's health summit in San Francisco, addressing what Christina Farr calls "the massive opportunity in women's longevity": a market that has overwhelmingly focused on men, despite the fact that women's biology requires a fundamentally different approach. Forbes ran a column last week titled "Rethinking Aging: Why Healthspan Should Be The Goal". The framing has shifted from "will people care about longevity?" to "can clinical practice absorb what's coming?"
But enthusiasm needs guardrails. A Case Western Reserve study published last week found that popular anti-ageing supplements (vitamin B3 derivatives like NR and NMN) may actually help cancer cells survive and resist treatment. The longevity consumer market needs rigorous science, not just hype.
The sector's real bottleneck isn't discovery. It's delivery. The gap between what science can now produce and what clinical practice can absorb is the defining tension of 2026.
That's what makes this quarter different from the hype cycles that came before. The money is real. The science is maturing. The events circuit is booming. And the hard questions about implementation, safety, and access are finally being asked at the same volume as the promises.
💥 May this inspire you to look at longevity not as a future category, but as one that's already reshaping the present.